In Duchenne muscular dystrophy, decline goes one direction.
Muscle is replaced by fibrous tissue and fat, and function does not come back. Boys typically lose the ability to walk in their early teens, and after that the arms are what is left - what a boy uses to feed himself, use a phone, hold a book, drive a chair.
Losing that is the part families dread most, and it has been treated as a matter of when rather than whether.
On July 29 The Lancet published the final one-year results of HOPE-3, a randomised, double-blind, placebo-controlled Phase 3 trial of a cell therapy called deramiocel in 106 participants [1].
The trial met its primary endpoint. On the Performance of the Upper Limb 2.0 scale, decline was slowed by 54 percent against placebo, at p=0.03 [1].
Craig McDonald, the trial's national principal investigator and a Distinguished Professor at UC Davis Health, put the finding in the terms that matter:
'A 54 percent slowing of upper limb disease progression (p=0.03) is a substantial, meaningful effect in a population where functional decline is typically relentless and irreversible' [1].
Note the words he chose. Relentless and irreversible. That is the baseline this number is measured against.
The trial also reported benefits across several cardiac measures [1], which matters because heart failure is what eventually kills most people with Duchenne.
The trial investigator's own institution describes the result independently of the manufacturer. UC Davis Health, where Craig McDonald chairs the Department of Physical Medicine and Rehabilitation, says patients on deramiocel experienced 'significantly slower disease progression,' and quotes him on why the arm matters: 'What makes these findings especially meaningful is that deramiocel demonstrated effects across multiple systems impacted by Duchenne muscular dystrophy. Preserving arm and hand function is critically important for maintaining independence and quality of life in people living with Duchenne' [2].
One precision worth keeping: the 54 percent figure and the p-value come from the company's release and the Lancet paper behind it. UC Davis confirms the trial and the direction of the result without restating that number.
Linda Marban, Capricor's chief executive, said 'The totality of evidence for Deramiocel is strong, with clinically meaningful benefits now published in The Lancet' [1].
Two honest limits, stated plainly because they are real.
This is not an approved treatment. Deramiocel remains investigational, with its licence application under active FDA review and a target action date of August 22, 2026 - three weeks away [1].
A trial of 106 participants is a small trial. That is normal for a rare disease, and it is still a small trial.
A 54 percent slowing is not a cure, and nobody involved has called it one.
What it is, is the first time the word irreversible has had a number put against it in this part of the disease.
